Pass Medicare Coverage for Multi-Cancer Early Detection Screening

hr842119

Nancy Gardner Sewell...

Less

Bill ID

hr842-119

TITLE

Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

STATUS

Introduced

Last Action on 01/31/2025: [1000] Introduced in House

COMMITTEES

VERSIONS

INTRODUCED

email advocacy

Pass Medicare Coverage for Multi-Cancer Early Detection Screening

Dear [Your Elected Official],

I am writing to urge you to continue to prioritize the health and well-being of the more than 60 million Americans on Medicare by passing the Nancy Gardner Sewell Medicare Multi-Cancer Detection Screening Act (H.R. 842). The Senate's passage of the Act (S. 339) on January 30, 2026 is a historic moment, that if passed by the House, could save thousands of lives annually. Now it is up to you.

Every day, approximately 1,700 Americans die from cancer, totaling over 600,000 deaths annually. Early cancer detection saves lives, reduces treatment costs, and improves the quality of life for patients and their families. When detected early, the five-year survival rate for cancer is nearly 90%.

We are encouraged by ongoing clinical trials demonstrating the effectiveness of multi-cancer early detection (MCED) tests, which can detect multiple types of cancer at earlier, more treatable stages through a simple blood test.

As a member of the cystic fibrosis (CF) community, I am especially passionate about broadening access to life-saving healthcare tools for vulnerable populations. While CF is primarily known as a lung condition, it also increases the risk of cancer. Over 11% of CF-related deaths in 2024 were attributed to cancer. In addition to those with CF aged 65 and above, many individuals with CF under age 65 rely on Medicare through their Social Security Disability Insurance status (41.2%). Access to MCED screening is therefore critical to large portions of our community.

We appreciate your leadership in supporting this important legislation. We urge the House to act swiftly to pass H.R. 842 and ensure Medicare beneficiaries have access to these transformative early detection tests.

Sincerely,

[Your Name]

[Your City & State]

Send me occasional emails about this issue

Summary

The bipartisan Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (MCED) (H.R. 842 / S. 339) was passed by the Senate on January 30, 2026. Before it can be signed into law, the House of Representatives will vote on the MCED Act once more—likely tomorrow, February 3. The bill would ensure Medicare coverage for innovative FDA-approved early cancer detection tests beginning in 2028. To date, H.R. 842 has been cosponsored by 338 Representatives. As life expectancy for people with cystic fibrosis (CF) increases, the prevalence of cancer diagnoses follows suit. Over 40% of individuals with CF under age 65 rely on Medicare through their Social Security Disability Insurance status, in addition to those with CF reaching the age of 65. This bill has the potential to save and extend the quality of life for those with CF as well as millions of Americans through advanced and more comprehensive multi-cancer early detection (MCED) screening. Join CFRI in asking the House to again support screening today! NOTE: To see whether your Representative is a supporter of the Act, click on the bill below. You will be able to click on your state to see the list of cosponsors. If they are supporting the legislation, you can thank them in the optional “add your personal message” box.

Who will receive your email?

Your Federal Representative